Vivesto — M&A Activity 2011

May 12, 2011

News Details

Corporate | 12 May 2011 09:00

Oasmia Pharmaceutical AB: Oasmia Pharmaceutical AB, Sweden and Medison Pharma, Israel announce license and distribution agreement for Paclical(R) in Israel and Turkey

Oasmia Pharmaceutical AB / Key word(s): Alliance

12.05.2011 / 09:00

The agreement concerns license- and distribution rights to Oasmia's
pharmaceutical candidate Paclical(R) in Israel and Turkey. Oasmia receives
400 000 Euro in up-front and milestone payments and additional royalties on
all sales in the region. Medison receives exclusive sales and marketing
rights to the candidate.

Medison is an Israeli pharmaceutical company with about 140 employees. The
company specializes in niched pharmaceuticals and has several strong
partners.

This is the second agreement for Paclical(R). Oasmia has previously closed
a license and distribution agreement for the Nordics with Orion
Corporation, Finland.

• We are very pleased to announce a new agreement for Paclical. Medison is
  a highly regarded company in their region and our cooperation will be very
  beneficial to the continued development of Oasmia, comments Oasmia's CEO
  Julian Aleksov.

• We are proud to expand our portfolio with Paclical. It will be part of
  our vast Oncology line and it's a great annunciation for the patients and
  health community in Israel and Turkey. We are delighted to collaborate in
  Turkey with Gen Ilac, a leading company with whom we have enjoyed a long
  term collaboration, comments Medison's President & CEO Meir Jakobsohn.

About Paclical(R)
With the retinoid based unique platform XR-17, Oasmia has managed to
develop a water soluble formulation of Paclitaxel (Paclical(R)) that does
not require premedication, allows a significantly higher dose and shows a
different side effect profile compared to Taxol(R). The main indications
are ovarian cancer and lung cancer.

About Medison
Medison Pharma Ltd, headquartered in Petach Tikva, Israel, is Israel's
leading marketing group, representing innovative pharmaceuticals, medical
devices and diagnostic products. Medison provides the complete spectrum of
integrated services for international companies looking to enter or expand
their presence in the Israeli, Romanian and Slovakian healthcare markets.
Medison has long term collaborations with companies such as Amgen, Biogen,
Shire, Ipsen and Boston scientific. Medison employs a comprehensive
approach to sales and service, supplying HMOs (Health Maintenance
Organizations), Medical Centers and physicians. Aligned with the growing
trend toward integrating pharmaceuticals, medical devices and diagnostics,
Medison is taking a leading role in advancing personalized medicine and
healthcare toward more focused practice and treatment paradigms.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human
and veterinary oncology. The product development aims to manufacture novel
formulations based on well-established cytostatics which, in comparison
with current alternatives, show improved properties, a reduced side-effect
profile and an expanded therapeutic area The company has developed several
unique formulations based on the platform XR-17: Paclical(R) (paclitaxel),
Doxophos(R) (doxorubicin), Docecal(R) (docetaxel) and Carbomexx(R)
(carboplatin). The product development is based on in-house research within
nanotechnology and company patents. The company was registered in 1999 and
is located in Uppsala, Sweden.

For more information, please contact: Maria Lundén, Head of Public
Relations, Oasmia Pharmaceutical AB.
E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contact : Dr.
Sönke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt E-Mail:
oasmia@edicto.de Phone: +49 (0) 69 90 55 05 52. Information is also
available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de

End of Corporate News

---

12.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

124244 12.05.2011